Clicky

SIGA Technologies Inc.(SIGA)

Description: SIGA Technologies, Inc. is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company’s lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug that targets orthopoxvirus infections. While TPOXX® is not yet approved as safe and effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug of which 2 million courses have been delivered to the Strategic National Stockpile under Project BioShield.


Keywords: Chemical Compounds Organic Chemistry Antiviral Drug Biological Warfare Monkeypox Small Molecule Poxviruses Orthopoxvirus U.S. Food & Drug Administration

Home Page: www.siga.com

SIGA Technical Analysis

31 East 62nd Street
New York, NY 10065
United States
Phone: 212 672 9100


Officers

Name Title
Dr. Phillip Louis Gomez III, M.D., Ph.D. CEO & Director
Mr. Daniel J. Luckshire Exec. VP, CFO & Sec.
Dr. Dennis E. Hruby Exec. VP & Chief Scientific Officer
Ms. Tove C. Bolken Sr. VP of Operations & Chief Supply Chain Officer
Mr. Herb Vloedman Sr. VP & Chief Information Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 8.547
Trailing PE: 5.2817
Price-to-Book MRQ: 3.4079
Price-to-Sales TTM: 2.584
IPO Date: 1997-09-09
Fiscal Year End: December
Full Time Employees: 39
Back to stocks